Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

VentiRx Completes Enrollment in Study of Orphan Cancer Drug

April 17, 2014 11:47 am | News | Comments

VentiRx Pharmaceuticals Inc. announced that enrollment has been completed in a Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. Read more...

TOPICS:

GSK Reports More Bribery Inquiries

April 17, 2014 11:24 am | News | Comments

British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. The company is also facing a corruption investigation in China and a bribery investigation in Poland and is looking into alleged bribery in Iraq. Read more...

TOPICS:

A Cinderella Story: Stem Cells in Personalized Medicine

April 17, 2014 11:00 am | Videos | Comments

In part four of our video series, Andrew Wiecek is back to discuss the role that induced pluripotent stem (iPS) cells play in personalized medicine. How do they help? Well, iPS cells are kind of like Cinderella's glass slipper. Watch more...

TOPICS:
Advertisement

'Matrix' Trial Will Advance Personalized Medicine for Lung Cancers

April 17, 2014 10:52 am | Videos | Comments

The "National Lung Matrix" trial, a partnership between Cancer Research UK, AstraZeneca and Pfizer, will give researchers unprecedented access to libraries of drugs developed by the companies, allowing several to be tested at the same time, within one trial. Read more...

TOPICS:

Cancer Drugs Block Dementia-Linked Brain Inflammation

April 17, 2014 10:40 am | News | Comments

A class of drugs developed to treat immune-related conditions and cancer– including one currently in clinical trials- eliminates neural inflammation associated with dementia-linked diseases and brain injuries, according to researchers. Read more...

TOPICS:

EC, FDA Give Orphan Status to Boehringer’s New Leukemia Drug

April 17, 2014 10:36 am | News | Comments

Boehringer Ingelheim Pharmaceuticals announced that the FDA and European Commission have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML). Read more...                   

TOPICS:

Vaccine Offers Survival Hope for Melanoma Patients

April 17, 2014 10:29 am | News | Comments

Researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability to stop or reverse the cancer. Read more...      

TOPICS:

Astellas to Pay $7.3M in Mycamine Marketing Settlement

April 17, 2014 10:13 am | News | Comments

A unit of Japanese drugmaker Astellas Pharma will pay the U.S. government $7.3 million to resolve claims it illegally marketed its antifungal drug Mycamine for children before that use was approved. Read more...            

TOPICS:
Advertisement

HPV Vaccine Works in HIV+ Women

April 16, 2014 2:00 pm | News | Comments

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial, countering doubts about whether the vaccine would be helpful. Read more...

TOPICS:

Phase 1 Results Positive for Tumor Vaccine

April 16, 2014 2:00 pm | News | Comments

Celldex Therapeutics Inc. announced that final data from its Phase 1 study of CDX-1401 (an off-the-shelf vaccine that targets dendritic cells) in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine. Read more...

TOPICS:

Measles Drug Lowers Viral Load

April 16, 2014 2:00 pm | News | Comments

A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers said. Read more...                  

TOPICS:

Small Molecule Shows Potential in Advanced Cancers

April 16, 2014 1:34 pm | News | Comments

Cleveland BioLabs Inc. announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. Read more...

TOPICS:

Baxter's Orphan Drug Candidate Hits Key Phase 3 Endpoint

April 16, 2014 1:06 pm | News | Comments

Baxter International Inc. announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics of BAX 111, a recombinant von Willebrand factor under investigation for the treatment of bleeding episodes in patients with von Willebrand disease. Read more...

TOPICS:

Recall Hurts Abbott, But Q1 Expectations Topped

April 16, 2014 1:00 pm | News | Comments

Abbott Laboratories' first-quarter net income tumbled 31% on unfavorable currency exchanges and a supplier recall that lowered sales of its baby formula, but the company beat most expectations and shares edged higher in early trading Wednesday. Read more...

TOPICS:

Researchers ID New Formulation for Cancer Treatment

April 16, 2014 11:20 am | News | Comments

Researchers have discovered a new way to deliver a tricky drug, dichloroacetate, that may one day make it a viable treatment for numerous forms of cancer. Read more...                       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading